TNF and Crohn disease: Ustekinumab was found to be effective in a phase 2a study conducted in patients with moderate-to-severe Crohn’s disease, and a randomized, double-blind phase 2b study showed an increased response rate in patients with moderate-to-severe Crohn’s disease in whom anti-TNF therapy was not effective [135].